Vindesine 4mg
| Product Overview | |
| Generic Name | Vindesine 4mg |
| Brand Name(s) | Eldisine® |
| Product Type | Generic |
| Form | Powder for solution for IV injection |
| Strength | 4 mg powder for solution, 5 mg vial |
| Therapeutic Class | Vinca alkaloid; tubulin/microtubule inhibitor; antimitotic cytotoxic agent. |
| ATC Code | L01CA03 |
| Manufacturing & Regulatory | |
| Manufacturer | Eli Lilly, Cipla, Aspen |
| Country | USA, India, Canada |
| GMP Compliance | WHO-GMP |
| COFEPRIS | n/a |
| Free Sale Certificate | Yes, available as COPP/CPP |
| Logistics & Export | |
| MOQ | 10 Units |
| Shelf Life | 24 Months |
| Storage | 2–8 °C, protect from light |
| Incoterms | EXW, HSN 30049099 |
| Lead Time | 7 - 10 Business Days |
| Documentation | |
| Certificate of Analysis (COA) | Supplied per batch upon request |
| CTD Summary | CTD from originator; generic use abbreviated formats |
Description
Vindesine is a semisynthetic vinca alkaloid chemotherapy used in selected malignancies, including acute lymphocytic leukemia, blastic crisis of chronic myeloid leukemia, non-small-cell lung cancer, melanoma, breast cancer, and lymphomas, depending on jurisdiction and protocol. It works by inhibiting tubulin/microtubule function and arresting mitosis.
